February 16th 2022
February 15th 2022
February 15th 2022
A Milestone in RSV Prevention: FDA Approves Pfizer's Abrysvo Vaccine for Older AdultsJune 1st 2023
The FDA's decision to approve Abrysvo was based on data from a Phase 3 clinical trial, which demonstrated the RSV vaccine's efficacy, immunogenicity, and safety in adults aged 60 and older.
Symptom Scoring Framework Paves the Way for Long COVID Definition
Analysis of symptoms present six months or more after SARS-CoV-2 infection was used to develop a composite scoring framework for identifying postacute sequelae of SARS-CoV-2 infection (PASC) as a new condition.
Xacduro, A New Weapon in the Fight Against Bacterial Pneumonia: Insights From Clinical Trials and Expert InterviewsMay 26th 2023
The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.
FDA Approves Paxlovid for COVID-19 in Adults, Continues Strategy to Minimize Infection SeverityMay 25th 2023
This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Evaluating the Benefits and Risks of Fecal Microbiota Transplantation for Recurrent C diffMay 25th 2023
FMT is a promising intervention for immunocompetent patients with recurrent C difficile infection. However, the safety of FMT remains inconclusive due to limited data on serious adverse events and mortality.
FDA Approves Sulbactam-Durlobactam for Bacterial PneumoniaMay 23rd 2023
The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.